Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 11/20 | 0.77 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.77 |
| ▸ | CCNB2 | O95067 | 10/20 | 0.77 |
| ▸ | CCNB3 | Q8WWL7 | 10/20 | 0.77 |
| ▸ | RET | P07949 | 13/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517500 | 0.87 | FLT3 (0.60) | CDK1CCNB1CCNB2CCNB3RET | |
| SCHEMBL13007924 | 0.87 | CDK1 (1.00) | CDK1CCNB1CCNB2CCNB3RET | |
| SCHEMBL2544992 | 0.85 | CCNB2 (1.00) | CDK1CCNB1CCNB2CCNB3RET | |
| SCHEMBL3247310 | 0.84 | CDK1 (0.79) | CDK1CCNB1CCNB2CCNB3RET | |
| SCHEMBL3773731 | 0.84 | CDK1 (0.79) | CDK1CCNB1CCNB2CCNB3RET | |
| SCHEMBL3781298 | 0.84 | CCNB2 (0.79) | CDK1CCNB1CCNB2CCNB3RET | |
| SCHEMBL3776459 | 0.84 | CDK1 (0.77) | CDK1CCNB1CCNB2CCNB3RET | |
| SCHEMBL13007936 | 0.84 | RET (1.00) | CDK1CCNB1CCNB2CCNB3RET | |
| SCHEMBL12723414 | 0.82 | DYRK1A (0.53) | CDK1CCNB1CCNB2CCNB3RET | |
| SCHEMBL3769950 | 0.82 | CDK1 (0.73) | CDK1CCNB1CCNB2CCNB3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20060183900-A1 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183900-A1 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | TK1, MAP3K1, MAP3K2 | CDK1 71/4885CCNB1 441/4885CCNB2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.